New Tool Reveals How Cancer Cells Rewrite Genetic Instructions
Cancer arises from genetic mutations, but a crucial factor in its development and progression lies in how a gene’s instructions are modified before being translated into proteins. A new study published in Nature Communications unveils a novel method for directly measuring this editing process, known as RNA splicing, offering a clearer understanding of how tumors adapt and survive—and potentially revealing new therapeutic targets.
Understanding RNA Splicing and Its Role in Cancer
Inside cells, genetic instructions are initially copied into temporary messages. Before these messages are used to create proteins, a process called splicing removes certain segments and joins the remaining parts together. This editing step allows a single gene to produce various proteins, essential for the complexity of life. However, almost all cancers hijack this cellular splicing process, altering how messages are cut and pasted to produce protein variants that promote faster growth, immune evasion, and treatment resistance. Dysregulated RNA splicing is a molecular feature that characterizes almost all tumour types.
From Editors to Edits: A New Approach
Traditionally, scientists have focused on measuring the molecules responsible for editing, known as splicing factors. However, these factors are subject to complex regulation, making it difficult to accurately assess their activity. The research team at the Centre for Genomic Regulation in Barcelona and Columbia University took a different approach: measuring the edits themselves, rather than the editors.
The researchers adapted a technology called VIPER (Virtual Inference of Protein Activity by Enriched Regulon analysis) to measure which segments of a gene’s message are retained or removed. These patterns act as fingerprints, revealing the true extent of editing activity, regardless of how the splicing factors are regulated. Exon inclusion signatures enable accurate estimation of splicing factor activity.
Identifying Cancer-Specific Splicing Programs
Applying this technique to approximately 10,000 tumor biopsies from 14 different cancer types within The Cancer Genome Atlas, researchers identified two broad cellular editing programs consistently appearing across all cancer types. One program acted as an “accelerator,” becoming more active in tumors and correlating with poorer patient outcomes. The other functioned as a “brake,” losing strength in cancer and associating with better survival rates.
This discovery suggests that cancers, despite their diversity, share common editing strategies that were previously obscured by focusing solely on genes. The analysis pinpointed around 120 potential new therapeutic targets – molecules that could be manipulated to restore balance to the cell’s editing machinery. A gene called FUS, typically associated with neurological conditions, emerged as a particularly strong candidate for further investigation.
Beyond Cancer: Broad Implications for Disease Research
The versatility of this technique extends beyond cancer research. Because it focuses on the outcome of genetic editing rather than the underlying cause, it can be applied to various diseases where cells alter their message assembly, including neurological and immune disorders. As Dr. Miquel Anglada Girotto, the study’s first author, explains, “We started with cancer because the data was available, but the approach could work for any disease where cells change how they edit their messages.”
“Instead of counting parts, our approach has been to understand behaviour, which has unlocked a new way of navigating a tumour’s chaotic biology. It’s early, but it gives us a much clearer map of where to look to find new ways of targeting the disease,” Dr. Anglada Girotto added.